Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IITerminatedFeb 20, 2019Prednisolone and Moxifloxacin Ophthalmic Solution 1%/0.5%Lack of sterility assurance.Promise Pharmacy, LLC · D-0432-2019Class IITerminatedFeb 20, 2019Acetylcysteine Ophthalmic SolutionLack of sterility assurance.Promise Pharmacy, LLC · D-0431-2019Class ITerminatedFeb 13, 2019the silver bullet 10x CapsulesMarketed without an Approved NDA/ANDA; FDA analysis found product to be tainted with undeclared sildenafil and tadalafilNatures Rx · D-0500-2019Class IIITerminatedFeb 13, 2019Bimatoprost Ophthalmic Solution 0.03%Failed Impurities/Degradation Specifications: OOS results observed in any other individual impurity and total impurities.Lupin Pharmaceuticals Inc. · D-0429-2019Class IITerminatedFeb 13, 2019Medline Remedy Essential Barrier Skin Protectant OintmentGMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sampleUS Pharmaceuticals Inc. · D-0427-2019Class IITerminatedFeb 13, 2019Hydrocortisone Cream 1% MS Anti itch Cream with Intensive Healing 2 oz tubesGMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sampleUS Pharmaceuticals Inc. · D-0426-2019Class IITerminatedFeb 13, 2019Soothe & Cool Protect Moisture Guard Skin ProtectantGMP Deviations: Out of specification results for Total Aerobic Microbial count in excipient purified water sampleUS Pharmaceuticals Inc. · D-0425-2019Class IITerminatedFeb 13, 2019DymistaDefective Container: Potential for broken glass in the neck area of the glass bottles.Mylan Pharmaceuticals Inc. · D-0424-2019Class IITerminatedFeb 6, 2019Fexofenadine HCl TabletsFailed Impurities/Degradation Specifications: Related compound results obtained during routine stability testing was slightly elevated above specification.Mylan Pharmaceuticals Inc. · D-0428-2019Class IITerminatedFeb 6, 2019Cephalexin for Oral Suspension USP 250mg/5 mLCGMP Deviations; presence of extraneous material in the was observed in area that is between the primary package that is heat sealed and secondary packaging (poly-woven...Lupin Pharmaceuticals Inc. · D-0423-2019Class IITerminatedFeb 6, 2019BromSiteBromfenac Ophthalmic Solution, 0.075% (Sterile 5 mL) may have a lack of sterility assurance.Sun Pharmaceutical Industries, Inc. · D-0422-2019Class IITerminatedFeb 6, 2019Domperidone 10 mg capsulesLack of Processing Controls.Duren Health Mart Pharmacy · D-0421-2019Class IITerminatedFeb 6, 2019Progesterone 100 mg SR capsulesLack of Processing Controls.Duren Health Mart Pharmacy · D-0420-2019Class IITerminatedFeb 6, 2019Promethazine Gel 50 mg/mLLack of Processing Controls.Duren Health Mart Pharmacy · D-0419-2019Class IITerminatedFeb 6, 2019Testosterone 0.1% creamLack of Processing Controls.Duren Health Mart Pharmacy · D-0418-2019Class IITerminatedFeb 6, 2019Progesterone 10% creamLack of Processing Controls.Duren Health Mart Pharmacy · D-0417-2019Class IITerminatedFeb 6, 2019Omeprazole 4 mg/mL SuspensionLack of Processing Controls.Duren Health Mart Pharmacy · D-0416-2019Class IITerminatedFeb 6, 2019GENTAMICIN OPTH-SOL 5ml Compare: Garamycin. 5-mL plastic dropper bottlePresence of Particulate Matter: Crystalline particles were noticed by manufacturer at the 24 month clarity testing.H J Harkins Company Inc dba Pharma Pac · D-0415-2019Class IITerminatedFeb 6, 2019Gentamicin Sulfate Ophthalmic SolutionPresence of Particulate Matter: Crystalline particles were noticed at the 24 month clarity testing.Akorn, Inc. · D-0414-2019Class IICompletedFeb 6, 2019Irbesartan and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Prinston Pharmaceutical Inc · D-0413-2019Class IICompletedFeb 6, 2019Irbesartan and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Prinston Pharmaceutical Inc · D-0412-2019Class IICompletedFeb 6, 2019Irbesartan and Hydrochlorothiazide TabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Prinston Pharmaceutical Inc · D-0411-2019Class IICompletedFeb 6, 2019Irbesartan and HydrochlorothiazideTabletsCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Prinston Pharmaceutical Inc · D-0410-2019Class IICompletedFeb 6, 2019Irbesartan Tablets 300 mgCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Prinston Pharmaceutical Inc · D-0409-2019Class IITerminatedJan 30, 2019HEPERAIN 50 mg/50 mLLabeling; Label Error on Declared Strength; label incorrectly states the concentration as 50 mg/50 mL (1 mg/mL) rather than the fully accurate concentration as 50...Advanced Pharma Inc. · D-0430-2019Class IIITerminatedJan 30, 2019LOPERAMIDE HCL TABLETS USPLabeling Not Elsewhere Classified: The front panel indicates 24 caplets whereas the side panel indicates 12 caplets. The drug product carton contains 24 caplets.Sun Pharmaceutical Industries, Inc. · D-0391-2019Class IITerminatedJan 30, 2019Fluocinolone Acetonide Topical SolutionFailed Impurities/Degradation Specifications: Expansion of October 2018 recall due to elevated out of specification results for total impurities that have been...Lupin Somerset · D-0390-2019Class IITerminatedJan 30, 2019Ezetimibe and Simvastatin Tablets 10mg/80 mgPresence of Foreign Substance: Product complaint of black speckles observed on tablets.Dr. Reddy's Laboratories, Inc. · D-0389-2019Class ITerminatedJan 30, 20195K Premium Enhancement capsuleMarketed without an Approved NDA/ANDA; FDA analysis found product to be tainted with undeclared sildenafil and tadalafilHappy Together, Inc. · D-0388-2019Class IITerminatedJan 30, 2019Curaplex Epi Kit NOT FOR IV USELabeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the...Bound Tree Medical, LLC · D-0386-2019Class IITerminatedJan 30, 2019Curaplex Epi Safe KitLabeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the...Bound Tree Medical, LLC · D-0385-2019Class IITerminatedJan 30, 2019curaplex Epi Safe KitLabeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the...Bound Tree Medical, LLC · D-0384-2019Class IITerminatedJan 30, 2019curaplex Epi Safe Administration and Training KitsLabeling Incorrect Instructions: This recall has been initiated because the Instructions for Use included in the Epi-Safe Kits for the Epi-Safe Syringe (and/or the...Bound Tree Medical, LLC · D-0383-2019Class IITerminatedJan 23, 2019Olmesartan Medoxomil and Hydrochlorothiazide TabletsFailed dissolution specificationsTeva Pharmaceuticals USA · D-0381-2019Class IITerminatedJan 23, 2019Cephalexin for Oral Suspension USPCGMP Deviation; manufacturing batch record could not be locatedLupin Pharmaceuticals Inc. · D-0380-2019Class IIITerminatedJan 23, 2019Curaplex Epi Safe KitLabeling: Incorrect or missing Lot and/or Exp Date:The Kit is incorrectly labeled as expiring May 2018 however the correct expiration date is May 2019. In addition...Bound Tree Medical, LLC · D-0379-2019Class IITerminatedJan 23, 2019EEMT (esterified estrogens and methyltestosterone) 1.25 mg/2.5 mgCGMP deviations: Lots were recalled due to sub-potency and cGMP violations.Syntho Pharmaceuticals, Inc. · D-0378-2019Class IITerminatedJan 23, 2019EEMT HSCGMP deviations: Lots were recalled due to sub-potency and cGMP violations.Syntho Pharmaceuticals, Inc. · D-0377-2019Class IITerminatedJan 23, 2019curaplex Epi Safe Administration and Training Kits # 8600-01100. Kit contains 2 Epi Safe Administration KitLabeling: Incorrect or Missing Lot and/or Exp date: vials of epinephrine within kit 8600-01100 expired on December 2018, but the outer kit label has an expiration date...Bound Tree Medical, LLC · D-0371-2019Class IIOngoingJan 23, 2019Valsartan tablets USP 320 mgCGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable...Aurobindo Pharma USA Inc. · D-0370-2019